Conference Material > Abstract
Nesbitt RC
Epicentre Scientific Day Paris 2023. 2023 June 8
BACKGROUND
Hepatitis E causes high mortality among pregnant women with case fatality risks of 10-25%, and adverse fetal outcomes. Hecolin® is a safe and efficacious vaccine against Hepatitis E, but there is an evidence gap on its safety in pregnant women. In 2015 the WHO recommended its use in response to outbreaks, including vaccinating pregnant women. The first mass reactive vaccination campaign against Hepatitis E was conducted in Bentiu including pregnant women and achieved high administrative vaccination coverage. We aimed to document pregnancy outcomes in a cohort of vaccinated and non-vaccinated pregnant women.
METHODS
An exhaustive pregnancy census was conducted after the second vaccination round from 16 May to 30 June 2022 to recruit women who were pregnant between 1 January 2022 and the interview date. Women were recontacted a minimum of 28 days after expected delivery to assess pregnancy outcome. Categorization of the cohort according to timing of potential vaccine exposure in pregnancy and regression models to evaluate the association between at least one dose in pregnancy and pregnancy outcomes is ongoing.
RESULTS
Of 20,674 women of childbearing age who consented for interview, 3,458 (16.7%) reported being pregnant since 1 January 2022. Women were a mean of 25.5 years old, had a median of 2 previous pregnancies (0-11), and 21 (0.6%) reported experiencing jaundice during their current pregnancy. Overall, 2723 (78.7%) women received at least one dose of Hecolin®. Access to delivery care was high, with 90% of women delivering in a health facility; 357 (10.3%) women reported a complication during delivery and 16 (0.5%) reported a caesarean section. According to interview, 3233 (93.5%) women had a livebirth, and 225 (6.9%) had a pregnancy loss, including 57 (1.6%) reported stillbirths, translating to a stillbirth rate of 17.6/1000 pregnancies, compared to the national estimate of 25.8/1000 pregnancies.
CONCLUSION
It was feasible to implement an observational study on the safety of vaccination in pregnancy alongside the first deployment of Hecolin® in a humanitarian emergency setting. Access to delivery care is reflected in the lower than national average rate of stillbirth in the camp. Results are expected to narrow the evidence gap on the safety of this vaccine in pregnancy.
KEY MESSAGE
A cohort study on the safety of vaccination in pregnancy was implemented alongside the first deployment of Hecolin® in a humanitarian emergency setting. Preliminary results show overall high coverage with at least one dose and access to delivery care among women in the cohort
This abstract is not to be quoted for publication.
Hepatitis E causes high mortality among pregnant women with case fatality risks of 10-25%, and adverse fetal outcomes. Hecolin® is a safe and efficacious vaccine against Hepatitis E, but there is an evidence gap on its safety in pregnant women. In 2015 the WHO recommended its use in response to outbreaks, including vaccinating pregnant women. The first mass reactive vaccination campaign against Hepatitis E was conducted in Bentiu including pregnant women and achieved high administrative vaccination coverage. We aimed to document pregnancy outcomes in a cohort of vaccinated and non-vaccinated pregnant women.
METHODS
An exhaustive pregnancy census was conducted after the second vaccination round from 16 May to 30 June 2022 to recruit women who were pregnant between 1 January 2022 and the interview date. Women were recontacted a minimum of 28 days after expected delivery to assess pregnancy outcome. Categorization of the cohort according to timing of potential vaccine exposure in pregnancy and regression models to evaluate the association between at least one dose in pregnancy and pregnancy outcomes is ongoing.
RESULTS
Of 20,674 women of childbearing age who consented for interview, 3,458 (16.7%) reported being pregnant since 1 January 2022. Women were a mean of 25.5 years old, had a median of 2 previous pregnancies (0-11), and 21 (0.6%) reported experiencing jaundice during their current pregnancy. Overall, 2723 (78.7%) women received at least one dose of Hecolin®. Access to delivery care was high, with 90% of women delivering in a health facility; 357 (10.3%) women reported a complication during delivery and 16 (0.5%) reported a caesarean section. According to interview, 3233 (93.5%) women had a livebirth, and 225 (6.9%) had a pregnancy loss, including 57 (1.6%) reported stillbirths, translating to a stillbirth rate of 17.6/1000 pregnancies, compared to the national estimate of 25.8/1000 pregnancies.
CONCLUSION
It was feasible to implement an observational study on the safety of vaccination in pregnancy alongside the first deployment of Hecolin® in a humanitarian emergency setting. Access to delivery care is reflected in the lower than national average rate of stillbirth in the camp. Results are expected to narrow the evidence gap on the safety of this vaccine in pregnancy.
KEY MESSAGE
A cohort study on the safety of vaccination in pregnancy was implemented alongside the first deployment of Hecolin® in a humanitarian emergency setting. Preliminary results show overall high coverage with at least one dose and access to delivery care among women in the cohort
This abstract is not to be quoted for publication.
Conference Material > Abstract
Nesbitt RC
Epicentre Scientific Day Paris 2022. 2022 June 1
BACKGROUND
Hepatitis E (HEV) is likely the most common cause of acute viral hepatitis and jaundice worldwide. The virus causes high mortality among pregnant women with case fatality risks of 10-25%, and adverse fetal outcomes. A safe and efficacious 3- dose recombinant vaccine (Hecolin®) has been licensed in China since 2011 and considered for use during outbreaks by the WHO since 2015. South Sudan has reported confirmed Hepatitis E cases for over a decade, with protracted outbreaks occurring in camps of displaced people. Bentiu IDP camp in Unity States hosts over 100,000 people displaced from conflict and flooding. A large outbreak of hepatitis E occurred in 2015, and despite numerous interventions, cases and deaths continue. In response, the MoH and MSF planned the first mass reactive vaccination campaign of the Hecolin® vaccine.
METHODS
The first round of vaccination started on 22 March 2022 and second round on 19 April 2022. The target population was 26,686 individuals aged 16-40 years residing in Bentiu IDP camp. Operational research alongside the vaccination campaign, including clinical surveillance at MSF Bentiu hospital, a case-control study, and a pregnancy cohort, is ongoing to document feasibility, safety and two-dose vaccine effectiveness.
RESULTS
Using a combination of fixed and mobile sites, 49,903 doses were administered during the two rounds of vaccination. Based on administrative population counts, coverage in the first round was 91% and second round was 95%. Clinical surveillance documented 288 suspect hepatitis E cases and 2 deaths from 21 March – 15 May, 2022. Among them, 61.5% of cases and both deaths were children less than 16 years, ineligible for vaccination. HEV IgM RDT positivity overall was 41.6%; 74.6% of RDT confirmed cases had elevated ALT (≥2.5-times ULN) and 29.7% of suspect cases testing negative.
CONCLUSION
The deployment of Hecolin® in a humanitarian emergency setting achieved high administrative vaccination coverage. This experience and the anticipated research results could allow for broader use of the vaccine in the fight against epidemics caused by hepatitis E virus.
KEY MESSAGE
The first mass reactive vaccination campaign against Hepatitis E was conducted in Bentiu IDP camp, South Sudan with high administrative vaccination coverage. Most cases in Bentiu are ineligible for vaccination due to age limitations of the vaccine.
This abstract is not to be quoted for publication.
Hepatitis E (HEV) is likely the most common cause of acute viral hepatitis and jaundice worldwide. The virus causes high mortality among pregnant women with case fatality risks of 10-25%, and adverse fetal outcomes. A safe and efficacious 3- dose recombinant vaccine (Hecolin®) has been licensed in China since 2011 and considered for use during outbreaks by the WHO since 2015. South Sudan has reported confirmed Hepatitis E cases for over a decade, with protracted outbreaks occurring in camps of displaced people. Bentiu IDP camp in Unity States hosts over 100,000 people displaced from conflict and flooding. A large outbreak of hepatitis E occurred in 2015, and despite numerous interventions, cases and deaths continue. In response, the MoH and MSF planned the first mass reactive vaccination campaign of the Hecolin® vaccine.
METHODS
The first round of vaccination started on 22 March 2022 and second round on 19 April 2022. The target population was 26,686 individuals aged 16-40 years residing in Bentiu IDP camp. Operational research alongside the vaccination campaign, including clinical surveillance at MSF Bentiu hospital, a case-control study, and a pregnancy cohort, is ongoing to document feasibility, safety and two-dose vaccine effectiveness.
RESULTS
Using a combination of fixed and mobile sites, 49,903 doses were administered during the two rounds of vaccination. Based on administrative population counts, coverage in the first round was 91% and second round was 95%. Clinical surveillance documented 288 suspect hepatitis E cases and 2 deaths from 21 March – 15 May, 2022. Among them, 61.5% of cases and both deaths were children less than 16 years, ineligible for vaccination. HEV IgM RDT positivity overall was 41.6%; 74.6% of RDT confirmed cases had elevated ALT (≥2.5-times ULN) and 29.7% of suspect cases testing negative.
CONCLUSION
The deployment of Hecolin® in a humanitarian emergency setting achieved high administrative vaccination coverage. This experience and the anticipated research results could allow for broader use of the vaccine in the fight against epidemics caused by hepatitis E virus.
KEY MESSAGE
The first mass reactive vaccination campaign against Hepatitis E was conducted in Bentiu IDP camp, South Sudan with high administrative vaccination coverage. Most cases in Bentiu are ineligible for vaccination due to age limitations of the vaccine.
This abstract is not to be quoted for publication.
Journal Article > ResearchFull Text
Trop Med Int Health. 2021 October 12; Volume 26 (Issue 12); 1609-1615.; DOI:10.1111/tmi.13688
Conan N, Badawi M, Chihana ML, Wanjala S, Kingwara L, et al.
Trop Med Int Health. 2021 October 12; Volume 26 (Issue 12); 1609-1615.; DOI:10.1111/tmi.13688
BACKGROUND
HIV-positive individuals who maintain an undetectable viral load cannot transmit the virus to others. In 2012, an HIV population-based survey was conducted in Ndhiwa sub-county (Kenya) to provide information on the HIV local epidemic. We carried out a second survey 6 years after the first one, to assess progress in HIV diagnosis and care and differences in the HIV prevalence and incidence between the two surveys.
METHODS
A cross-sectional, population-based survey using cluster sampling and geospatial random selection was implemented in 2018, using the same design as 2012. Consenting participants aged 15-59 years were interviewed and tested for HIV at home. HIV-positive individuals received viral load testing (viral suppression defined as <1000 copies/ml) and Lag-Avidity EIA assay (to measure recent infection). The 90-90-90 UNAIDS indicators were also assessed.
RESULTS
Overall, 6029 individuals were included in 2018. HIV prevalence was 16.9%. Viral suppression among all HIV-positive was 88.3% in 2018 (vs. 39.9% in 2012, p < 0.001). HIV incidence was 0.75% in 2018 vs. 1.90% in 2012 (p = 0.07). In 2018, the 90-90-90 indicators were 93%-97%-95% (vs. 60%-68%-83% in 2012).
CONCLUSIONS
A two-fold increase in the HIV viral load suppression rate along with a decreasing trend in incidence was observed over 6 years in Ndhiwa sub-county. Achieving high rates of viral suppression in HIV populations that can lead to reducing HIV transmission in sub-Saharan contexts is feasible. Nevertheless, we will need further efforts to sustain this progress.
HIV-positive individuals who maintain an undetectable viral load cannot transmit the virus to others. In 2012, an HIV population-based survey was conducted in Ndhiwa sub-county (Kenya) to provide information on the HIV local epidemic. We carried out a second survey 6 years after the first one, to assess progress in HIV diagnosis and care and differences in the HIV prevalence and incidence between the two surveys.
METHODS
A cross-sectional, population-based survey using cluster sampling and geospatial random selection was implemented in 2018, using the same design as 2012. Consenting participants aged 15-59 years were interviewed and tested for HIV at home. HIV-positive individuals received viral load testing (viral suppression defined as <1000 copies/ml) and Lag-Avidity EIA assay (to measure recent infection). The 90-90-90 UNAIDS indicators were also assessed.
RESULTS
Overall, 6029 individuals were included in 2018. HIV prevalence was 16.9%. Viral suppression among all HIV-positive was 88.3% in 2018 (vs. 39.9% in 2012, p < 0.001). HIV incidence was 0.75% in 2018 vs. 1.90% in 2012 (p = 0.07). In 2018, the 90-90-90 indicators were 93%-97%-95% (vs. 60%-68%-83% in 2012).
CONCLUSIONS
A two-fold increase in the HIV viral load suppression rate along with a decreasing trend in incidence was observed over 6 years in Ndhiwa sub-county. Achieving high rates of viral suppression in HIV populations that can lead to reducing HIV transmission in sub-Saharan contexts is feasible. Nevertheless, we will need further efforts to sustain this progress.
Journal Article > ResearchFull Text
BMC Public Health. 2022 February 14; Volume 22 (Issue 1); 295.; DOI: 10.1186/s12889-022-12547-9
Gerstl S, Lee L, Nesbitt RC, Mambula C, Sugianto H, et al.
BMC Public Health. 2022 February 14; Volume 22 (Issue 1); 295.; DOI: 10.1186/s12889-022-12547-9
BACKGROUND
Cervical cancer (CC) is the fourth most common cancer among women worldwide and Malawi has the world's highest rate of cervical cancer related mortality. Since 2016 the National CC Control Strategy has set a screening coverage target at 80% of 25-49-year-old women. The Ministry of Health and Médecins Sans Frontières (MSF) set up a CC program in Blantyre City, as a model for urban areas, and Chiradzulu District, as a model for rural areas. This population-based survey aimed to estimate CC screening coverage and to understand why women were or were not screened.
METHODS
A population-based survey was conducted in 2019. All resident consenting eligible women aged 25-49 years were interviewed (n = 1850) at households selected by two-stage cluster sampling. Screening and treatment coverage and facilitators and barriers to screening were calculated stratified by age, weighted for survey design. Chi square and design-based F tests were used to assess relationship between participant characteristics and screening status.
RESULTS
The percentage of women ever screened for CC was highest in Blantyre at 40.2% (95% CI 35.1-45.5), 38.9% (95% CI 32.8-45.4) in Chiradzulu with supported CC screening services, and lowest in Chiradzulu without supported CC screening services at 25.4% (95% CI 19.9-31.8). Among 623 women screened, 49.9% (95% CI 44.0-55.7) reported that recommendation in the health facility was the main reason they were screened and 98.5% (95% CI 96.3-99.4) recommended CC screening to others. Among 1227 women not screened, main barriers were lack of time (26.0%, 95% CI 21.9-30.6), and lack of motivation (18.3%, 95% CI 14.1-23.3). Overall, 95.6% (95% CI 93.6-97.0) of women reported that they had some knowledge about CC. Knowledge of CC symptoms was low at 34.4% (95% CI 31.0-37.9) and 55.1% (95% CI 51.0-59.1) of participants believed themselves to be at risk of CC.
CONCLUSION
Most of the survey population had heard about CC. Despite this knowledge, fewer than half of eligible women had been screened for CC. Reasons given for not attending screening can be addressed by programs. To significantly reduce mortality due to CC in Malawi requires a comprehensive health strategy that focuses on prevention, screening and treatment.
Cervical cancer (CC) is the fourth most common cancer among women worldwide and Malawi has the world's highest rate of cervical cancer related mortality. Since 2016 the National CC Control Strategy has set a screening coverage target at 80% of 25-49-year-old women. The Ministry of Health and Médecins Sans Frontières (MSF) set up a CC program in Blantyre City, as a model for urban areas, and Chiradzulu District, as a model for rural areas. This population-based survey aimed to estimate CC screening coverage and to understand why women were or were not screened.
METHODS
A population-based survey was conducted in 2019. All resident consenting eligible women aged 25-49 years were interviewed (n = 1850) at households selected by two-stage cluster sampling. Screening and treatment coverage and facilitators and barriers to screening were calculated stratified by age, weighted for survey design. Chi square and design-based F tests were used to assess relationship between participant characteristics and screening status.
RESULTS
The percentage of women ever screened for CC was highest in Blantyre at 40.2% (95% CI 35.1-45.5), 38.9% (95% CI 32.8-45.4) in Chiradzulu with supported CC screening services, and lowest in Chiradzulu without supported CC screening services at 25.4% (95% CI 19.9-31.8). Among 623 women screened, 49.9% (95% CI 44.0-55.7) reported that recommendation in the health facility was the main reason they were screened and 98.5% (95% CI 96.3-99.4) recommended CC screening to others. Among 1227 women not screened, main barriers were lack of time (26.0%, 95% CI 21.9-30.6), and lack of motivation (18.3%, 95% CI 14.1-23.3). Overall, 95.6% (95% CI 93.6-97.0) of women reported that they had some knowledge about CC. Knowledge of CC symptoms was low at 34.4% (95% CI 31.0-37.9) and 55.1% (95% CI 51.0-59.1) of participants believed themselves to be at risk of CC.
CONCLUSION
Most of the survey population had heard about CC. Despite this knowledge, fewer than half of eligible women had been screened for CC. Reasons given for not attending screening can be addressed by programs. To significantly reduce mortality due to CC in Malawi requires a comprehensive health strategy that focuses on prevention, screening and treatment.
Journal Article > ResearchFull Text
PLoS Negl Trop Dis. 2024 January 22; Volume 18 (Issue 1); e0011661.; DOI:10.1371/journal.pntd.0011661
Nesbitt RC, Asilaza VK, Gignoux EM, Koyuncu A, Gitahi P, et al.
PLoS Negl Trop Dis. 2024 January 22; Volume 18 (Issue 1); e0011661.; DOI:10.1371/journal.pntd.0011661
INTRODUCTION
Hepatitis E (HEV) genotypes 1 and 2 are the common cause of jaundice and acute viral hepatitis that can cause large-scale outbreaks. HEV infection is associated with adverse fetal outcomes and case fatality risks up to 31% among pregnant women. An efficacious three-dose recombinant vaccine (Hecolin) has been licensed in China since 2011 but until 2022, had not been used for outbreak response despite a 2015 WHO recommendation. The first ever mass vaccination campaign against hepatitis E in response to an outbreak was implemented in 2022 in Bentiu internally displaced persons camp in South Sudan targeting 27,000 residents 16–40 years old, including pregnant women.
METHODS
We conducted a vaccination coverage survey using simple random sampling from a sampling frame of all camp shelters following the third round of vaccination. For survey participants vaccinated in the third round in October, we asked about the onset of symptoms experienced within 72 hours of vaccination. During each of the three vaccination rounds, passive surveillance of adverse events following immunisation (AEFI) was put in place at vaccination sites and health facilities in Bentiu IDP camp.
RESULTS
We surveyed 1,599 individuals and found that self-reported coverage with one or more dose was 86% (95% CI 84–88%), 73% (95% CI 70–75%) with two or more doses and 58% (95% CI 55–61%) with three doses. Vaccination coverage did not differ significantly by sex or age group. We found no significant difference in coverage of at least one dose between pregnant and non-pregnant women, although coverage of at least two and three doses was 8 and 14 percentage points lower in pregnant women. The most common reasons for non-vaccination were temporary absence or unavailability, reported by 60% of unvaccinated people. Passive AEFI surveillance captured few mild AEFI, and through the survey we found that 91 (7.6%) of the 1,195 individuals reporting to have been vaccinated in October 2022 reported new symptoms starting within 72 hours after vaccination, most commonly fever, headache or fatigue.
CONCLUSIONS
We found a high coverage of at least one dose of the Hecolin vaccine following three rounds of vaccination, and no severe AEFI. The vaccine was well accepted and well tolerated in the Bentiu IDP camp community and should be considered for use in future outbreak response.
Hepatitis E (HEV) genotypes 1 and 2 are the common cause of jaundice and acute viral hepatitis that can cause large-scale outbreaks. HEV infection is associated with adverse fetal outcomes and case fatality risks up to 31% among pregnant women. An efficacious three-dose recombinant vaccine (Hecolin) has been licensed in China since 2011 but until 2022, had not been used for outbreak response despite a 2015 WHO recommendation. The first ever mass vaccination campaign against hepatitis E in response to an outbreak was implemented in 2022 in Bentiu internally displaced persons camp in South Sudan targeting 27,000 residents 16–40 years old, including pregnant women.
METHODS
We conducted a vaccination coverage survey using simple random sampling from a sampling frame of all camp shelters following the third round of vaccination. For survey participants vaccinated in the third round in October, we asked about the onset of symptoms experienced within 72 hours of vaccination. During each of the three vaccination rounds, passive surveillance of adverse events following immunisation (AEFI) was put in place at vaccination sites and health facilities in Bentiu IDP camp.
RESULTS
We surveyed 1,599 individuals and found that self-reported coverage with one or more dose was 86% (95% CI 84–88%), 73% (95% CI 70–75%) with two or more doses and 58% (95% CI 55–61%) with three doses. Vaccination coverage did not differ significantly by sex or age group. We found no significant difference in coverage of at least one dose between pregnant and non-pregnant women, although coverage of at least two and three doses was 8 and 14 percentage points lower in pregnant women. The most common reasons for non-vaccination were temporary absence or unavailability, reported by 60% of unvaccinated people. Passive AEFI surveillance captured few mild AEFI, and through the survey we found that 91 (7.6%) of the 1,195 individuals reporting to have been vaccinated in October 2022 reported new symptoms starting within 72 hours after vaccination, most commonly fever, headache or fatigue.
CONCLUSIONS
We found a high coverage of at least one dose of the Hecolin vaccine following three rounds of vaccination, and no severe AEFI. The vaccine was well accepted and well tolerated in the Bentiu IDP camp community and should be considered for use in future outbreak response.
Journal Article > ResearchFull Text
J Int AIDS Soc. 2018 September 21; Volume 21 (Issue 9); DOI:10.1002/jia2.25183
Pasipamire L, Nesbitt RC, Ndlovu S, Sibanda G, Mamba S, et al.
J Int AIDS Soc. 2018 September 21; Volume 21 (Issue 9); DOI:10.1002/jia2.25183
A broad range of community-centred care models for patients stable on anti-retroviral therapy (ART) have been proposed by the World Health Organization to better respond to patient needs and alleviate pressure on health systems caused by rapidly growing patient numbers. Where available, often a single alternative care model is offered in addition to routine clinical care. We operationalized several community-centred ART delivery care models in one public sector setting. Here, we compare retention in care and on ART and identify predictors of disengagement with care.
Conference Material > Video (talk)
Nesbitt RC
Epicentre Scientific Day Paris 2023. 2023 June 8
English
Français
Conference Material > Video (talk)
Gerstl S, Nesbitt RC
Epicentre Scientific Day Paris 2021. 2021 June 10
Journal Article > ResearchFull Text
Lancet Public Health. 2021 April 1; Volume 6 (Issue 4); DOI:10.1016/s2468-2667(21)00001-3
Roederer T, Mollo B, Vincent C, Nikolay B, Llosa AE, et al.
Lancet Public Health. 2021 April 1; Volume 6 (Issue 4); DOI:10.1016/s2468-2667(21)00001-3
Between June 23 and July 2, 2020, 426 (52%) of 818 individuals recruited tested positive in 14 sites. Seroprevalence varied significantly by type of recruitment site (χ2 p<0·0001), being highest among those living in workers' residences (88·7%, 95% CI 81·8-93·2), followed by emergency shelters (50·5%, 46·3-54·7), and food distribution sites (27·8%, 20·8-35·7). More than two thirds of COVID-19 seropositive individuals (68%, 95% CI 64·2-72·2; 291 of 426) did not report any symptoms during the recall period. COVID-19 seropositivity was strongly associated with overcrowding (medium density: adjusted odds ratio [aOR] 2·7, 95% CI 1·5-5·1, p=0·0020; high density: aOR 3·4, 1·7-6·9, p<0·0001).
Conference Material > Poster
Ben-Farhat J, Nesbitt RC, Bjertrup PJ, Mambula C, Balkan S, et al.
MSF Scientific Days International 2022. 2022 May 9; DOI:10.57740/deah-n253